The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chong Kun Dang Pharmaceutical; CJ Healthcare; Green Cross; Janssen; Lilly; Menarini; Merck; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda
Consulting or Advisory Role - ST Cube
Travel, Accommodations, Expenses - Blueprint Medicines; Takeda
 
Aflah Roohullah
No Relationships to Disclose
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Charlotte Rose Lemech
No Relationships to Disclose
 
Paul L. de Souza
Consulting or Advisory Role - Biosceptre International
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MaxiNovel (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Jun Young Choi
Employment - Abiomed
Leadership - Abiomed
Stock and Other Ownership Interests - Abiomed
Patents, Royalties, Other Intellectual Property - Abiomed
 
Kyung Eui Park
Employment - Abiomed
Stock and Other Ownership Interests - Abiomed
Patents, Royalties, Other Intellectual Property - Abiomed
 
Minseon Lee
Employment - Abiomed
Stock and Other Ownership Interests - Abiomed
 
YeongMun Kim
Employment - Abiomed
Stock and Other Ownership Interests - Abiomed
Patents, Royalties, Other Intellectual Property - Abiomed
 
YOUNGKEE Shin
Employment - Abiomed
Leadership - Abiomed (Inst)
Stock and Other Ownership Interests - Abiomed (Inst)
Patents, Royalties, Other Intellectual Property - Abiomed (Inst)
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda